Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury
Wong JK., Deuschl G., Wolke R., Bergman H., Muthuraman M., Groppa S., Sheth SA., Bronte-Stewart HM., Wilkins KB., Petrucci MN., Lambert E., Kehnemouyi Y., Starr PA., Little S., Anso J., Gilron R., Poree L., Kalamangalam GP., Worrell GA., Miller KJ., Schiff ND., Butson CR., Henderson JM., Judy JW., Ramirez-Zamora A., Foote KD., Silburn PA., Li L., Oyama G., Kamo H., Sekimoto S., Hattori N., Giordano JJ., DiEuliis D., Shook JR., Doughtery DD., Widge AS., Mayberg HS., Cha J., Choi K., Heisig S., Obatusin M., Opri E., Kaufman SB., Shirvalkar P., Rozell CJ., Alagapan S., Raike RS., Bokil H., Green D., Okun MS.
DBS Think Tank IX was held on August 25–27, 2021 in Orlando FL with US based participants largely in person and overseas participants joining by video conferencing technology. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging deep brain stimulation (DBS) technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank IX speakers was that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. After collectively sharing our experiences, it was estimated that globally more than 230,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. As such, this year’s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia and Australia; cutting-edge technologies, neuroethics, interventional psychiatry, adaptive DBS, neuromodulation for pain, network neuromodulation for epilepsy and neuromodulation for traumatic brain injury.